There are also meglitinides, D-phenylalanine derivatives, α-glucosidase inhibitors, glucagon-like-peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose co-transporter-2 inhibitors, but studies analyzing the effects of these T2DM medications on the incidence of thyroid cancer are rare. This evidence concerns the gene DPP4 and thyroid cancer.